inclusion criteria 1. adults, age 18 - 50 years, inclusive, at time of first study vaccination. 2. able to understand and provide a signed informed consent that fulfils the relevant institutional review board (irb) or independent ethics committee (iec) guidelines. 3. agrees to the collection of biospecimens (e.g. nasopharyngeal \[np\] swabs) and venous blood per protocol. 4. ability to attend required study visits and return for adequate follow-up, as required by this protocol. 5. body mass index (bmi) \< 30.00 kg/m2 6. temperature \< 38.0°c on day of first study vaccination. 7. good general health as shown by medical history, physical exam, and screening laboratory tests 8. screen negative for tuberculosis per local screening guidelines 9. male participants should all be at low risk of hiv acquisition based on pre-specified, validated criteria(laher 2014) i.e. answering yes to any of the following questions: 1. are you sexually abstinent? 2. are you in a mutually monogamous relationship with a known hiv-uninfected partner? 3. have you had only one partner in the preceding 12 months who is believed to be hiv-uninfected and with whom condoms were used regularly? laboratory inclusion values/ results: 10. alanine aminotransferase (alt) \<1.1 times the upper limit of normal 11. serum creatinine \<80 umol/l in females and \<106 umol/l in males 12. haemoglobin \>12.0g/dl in females and \>13.5g/dl in males 13. platelets \>150 x 109/l in all participants 14. no serological evidence of chronic infection with hepatitis b (hepatitis b surface antigen (hepbsag) negative by a locally approved assay) done during the screening period 15. no serological evidence of chronic infection with hepatitis c (hepatitis c antibody(anti-hcv) negative by a locally approved assay) done during the screening period 16. negative for sars-cov-2 (qpcr test) on np swab(or other appropriate respiratory specimen) within 3 days prior to the first study vaccination 17. no serological evidence of prior infection with sars-cov-2 (by a locally approved assay) done during the screening period 18. a negative serum or urine pregnancy test during screening and on the day of and prior to each dose must be documented before the vaccine is administered to a female participant. 19. negative for hiv-1 and -2 on blood test(by either 2 rapid tests or an elisa, both must be locally approved assays) done during the screening period. reproductive status: 20. female participants of childbearing potential must agree to use effective contraception for sexual activity that may lead to pregnancy while on study until at least 30 days after the last dose of the study vaccine. effective contraception for female participants includes: * intrauterine device (iud), or * hormonal contraception (oral/ injectable/ implant/ transdermal etc.) or; 21. non-sterile male participants must agree to use a condom while on study until at least 30 days after the last dose of the study vaccine. or; 22. participant must not be of reproductive potential or sterile(as verified by medical records), such as: * having been diagnosed with menopause(with no menses for 1 year) * having undergone hysterectomy, bilateral oophorectomy or orchidectomy * having undergone surgical sterilization (e.g., vasectomy, tubal ligation)

inclusion criteria 1. adults, age 18 - 50 years, inclusive, at time of first study vaccination. 2. able to understand and provide a signed informed consent that fulfils the relevant institutional review board (irb) or independent ethics committee (iec) guidelines. 3. agrees to the collection of biospecimens (e.g. nasopharyngeal \[np\] swabs) and venous blood per protocol. 4. ability to attend required study visits and return for adequate follow-up, as required by this protocol. 5. body mass index (bmi) \< 30.00 kg/m2 6. temperature \< 38.0°c on day of first study vaccination. 7. good general health as shown by medical history, physical exam, and screening laboratory tests 8. screen negative for tuberculosis per local screening guidelines 9. male participants should all be at low risk of hiv acquisition based on pre-specified, validated criteria(laher 2014) i.e. answering yes to any of the following questions: 1. are you sexually abstinent? 2. are you in a mutually monogamous relationship with a known hiv-uninfected partner? 3. have you had only one partner in the preceding 12 months who is believed to be hiv-uninfected and with whom condoms were used regularly? laboratory inclusion values/ results: 10. alanine aminotransferase (alt) \<1.1 times the upper limit of normal 11. serum creatinine \<80 umol/l in females and \<106 umol/l in males 12. haemoglobin \>12.0g/dl in females and \>13.5g/dl in males 13. platelets \>150 x 109/l in all participants 14. no serological evidence of chronic infection with hepatitis b (hepatitis b surface antigen (hepbsag) negative by a locally approved assay) done during the screening period 15. no serological evidence of chronic infection with hepatitis c (hepatitis c antibody(anti-hcv) negative by a locally approved assay) done during the screening period 16. negative for sars-cov-2 (qpcr test) on np swab(or other appropriate respiratory specimen) within 3 days prior to the first study vaccination 17. no serological evidence of prior infection with sars-cov-2 (by a locally approved assay) done during the screening period 18. a negative serum or urine pregnancy test during screening and on the day of and prior to each dose must be documented before the vaccine is administered to a female participant. 19. negative for hiv-1 and -2 on blood test(by either 2 rapid tests or an elisa, both must be locally approved assays) done during the screening period. reproductive status: 20. female participants of childbearing potential must agree to use effective contraception for sexual activity that may lead to pregnancy while on study until at least 30 days after the last dose of the study vaccine. effective contraception for female participants includes: * intrauterine device (iud), or * hormonal contraception (oral/ injectable/ implant/ transdermal etc.) or; 21. non-sterile male participants must agree to use a condom while on study until at least 30 days after the last dose of the study vaccine. or; 22. participant must not be of reproductive potential or sterile(as verified by medical records), such as: * having been diagnosed with menopause(with no menses for 1 year) * having undergone hysterectomy, bilateral oophorectomy or orchidectomy * having undergone surgical sterilization (e.g., vasectomy, tubal ligation)

inclusion criteria adults, age 18 - 50 years, inclusive, at time of first study vaccination. able to understand and provide a signed informed consent that fulfils the relevant institutional review board (irb) or independent ethics committee (iec) guidelines. agrees to the collection of biospecimens (e.g. nasopharyngeal [np] swabs) and venous blood per protocol. ability to attend required study visits and return for adequate follow-up, as required by this protocol. body mass index (bmi) < 30.00 kg/m2 temperature < 38.0°c on day of first study vaccination. good general health as shown by medical history, physical exam, and screening laboratory tests screen negative for tuberculosis per local screening guidelines male participants should all be at low risk of hiv acquisition based on pre-specified, validated criteria(laher 2014) i.e. answering yes to any of the following questions: 1. are you sexually abstinent? 2. are you in a mutually monogamous relationship with a known hiv-uninfected partner? 3. have you had only one partner in the preceding 12 months who is believed to be hiv-uninfected and with whom condoms were used regularly? laboratory inclusion values/ results: 10. alanine aminotransferase (alt) <1.1 times the upper limit of normal 11. serum creatinine <80 umol/l in females and <106 umol/l in males 12. haemoglobin >12.0g/dl in females and >13.5g/dl in males 13. platelets >150 x 109/l in all participants 14. no serological evidence of chronic infection with hepatitis b (hepatitis b surface antigen (hepbsag) negative by a locally approved assay) done during the screening period 15. no serological evidence of chronic infection with hepatitis c (hepatitis c antibody(anti-hcv) negative by a locally approved assay) done during the screening period 16. negative for sars-cov-2 (qpcr test) on np swab(or other appropriate respiratory specimen) within 3 days prior to the first study vaccination 17. no serological evidence of prior infection with sars-cov-2 (by a locally approved assay) done during the screening period 18. a negative serum or urine pregnancy test during screening and on the day of and prior to each dose must be documented before the vaccine is administered to a female participant. 19. negative for hiv-1 and -2 on blood test(by either 2 rapid tests or an elisa, both must be locally approved assays) done during the screening period. reproductive status: 20. female participants of childbearing potential must agree to use effective contraception for sexual activity that may lead to pregnancy while on study until at least 30 days after the last dose of the study vaccine. effective contraception for female participants includes: intrauterine device (iud), or hormonal contraception (oral/ injectable/ implant/ transdermal etc.) or; 21. non-sterile male participants must agree to use a condom while on study until at least 30 days after the last dose of the study vaccine. or; 22. participant must not be of reproductive potential or sterile(as verified by medical records), such as: having been diagnosed with menopause(with no menses for 1 year) having undergone hysterectomy, bilateral oophorectomy or orchidectomy having undergone surgical sterilization (e.g., vasectomy, tubal ligation)

inclusion criteria adults, age 18 - 50 years, inclusive, at time of first study vaccination. able to understand and provide a signed informed consent that fulfils the relevant institutional review board (irb) or independent ethics committee (iec) guidelines. agrees to the collection of biospecimens (e.g. nasopharyngeal [np] swabs) and venous blood per protocol. ability to attend required study visits and return for adequate follow-up, as required by this protocol. body mass index (bmi) < 30.00 kg/m2 temperature < 38.0°c on day of first study vaccination. good general health as shown by medical history, physical exam, and screening laboratory tests screen negative for tuberculosis per local screening guidelines male participants should all be at low risk of hiv acquisition based on pre-specified, validated criteria(laher 2014) i.e. answering yes to any of the following questions: 1. are you sexually abstinent? 2. are you in a mutually monogamous relationship with a known hiv-uninfected partner? 3. have you had only one partner in the preceding 12 months who is believed to be hiv-uninfected and with whom condoms were used regularly? laboratory inclusion values/ results: 10. alanine aminotransferase (alt) <1.1 times the upper limit of normal 11. serum creatinine <80 umol/l in females and <106 umol/l in males 12. haemoglobin >12.0g/dl in females and >13.5g/dl in males 13. platelets >150 x 109/l in all participants 14. no serological evidence of chronic infection with hepatitis b (hepatitis b surface antigen (hepbsag) negative by a locally approved assay) done during the screening period 15. no serological evidence of chronic infection with hepatitis c (hepatitis c antibody(anti-hcv) negative by a locally approved assay) done during the screening period 16. negative for sars-cov-2 (qpcr test) on np swab(or other appropriate respiratory specimen) within 3 days prior to the first study vaccination 17. no serological evidence of prior infection with sars-cov-2 (by a locally approved assay) done during the screening period 18. a negative serum or urine pregnancy test during screening and on the day of and prior to each dose must be documented before the vaccine is administered to a female participant. 19. negative for hiv-1 and -2 on blood test(by either 2 rapid tests or an elisa, both must be locally approved assays) done during the screening period. reproductive status: 20. female participants of childbearing potential must agree to use effective contraception for sexual activity that may lead to pregnancy while on study until at least 30 days after the last dose of the study vaccine. effective contraception for female participants includes: intrauterine device (iud), or hormonal contraception (oral/ injectable/ implant/ transdermal etc.) or; 21. non-sterile male participants must agree to use a condom while on study until at least 30 days after the last dose of the study vaccine. or; 22. participant must not be of reproductive potential or sterile(as verified by medical records), such as: having been diagnosed with menopause(with no menses for 1 year) having undergone hysterectomy, bilateral oophorectomy or orchidectomy having undergone surgical sterilization (e.g., vasectomy, tubal ligation)

inclusion criteria 1. adults, age 18 - 50 years, inclusive, at time of first study vaccination. 2. able to understand and provide a signed informed consent that fulfils the relevant institutional review board (irb) or independent ethics committee (iec) guidelines. 3. agrees to the collection of biospecimens (e.g. nasopharyngeal [np] swabs) and venous blood per protocol. 4. ability to attend required study visits and return for adequate follow-up, as required by this protocol. 5. body mass index (bmi) < 30.00 kg/m2 6. temperature < 38.0°c on day of first study vaccination. 7. good general health as shown by medical history, physical exam, and screening laboratory tests 8. screen negative for tuberculosis per local screening guidelines 9. male participants should all be at low risk of hiv acquisition based on pre-specified, validated criteria(laher 2014) i.e. answering yes to any of the following questions: 1. are you sexually abstinent? 2. are you in a mutually monogamous relationship with a known hiv-uninfected partner? 3. have you had only one partner in the preceding 12 months who is believed to be hiv-uninfected and with whom condoms were used regularly? laboratory inclusion values/ results: 10. alanine aminotransferase (alt) <1.1 times the upper limit of normal 11. serum creatinine <80 umol/l in females and <106 umol/l in males 12. haemoglobin >12.0g/dl in females and >13.5g/dl in males 13. platelets >150 x 109/l in all participants 14. no serological evidence of chronic infection with hepatitis b (hepatitis b surface antigen (hepbsag) negative by a locally approved assay) done during the screening period 15. no serological evidence of chronic infection with hepatitis c (hepatitis c antibody(anti-hcv) negative by a locally approved assay) done during the screening period 16. negative for sars-cov-2 (qpcr test) on np swab(or other appropriate respiratory specimen) within 3 days prior to the first study vaccination 17. no serological evidence of prior infection with sars-cov-2 (by a locally approved assay) done during the screening period 18. a negative serum or urine pregnancy test during screening and on the day of and prior to each dose must be documented before the vaccine is administered to a female participant. 19. negative for hiv-1 and -2 on blood test(by either 2 rapid tests or an elisa, both must be locally approved assays) done during the screening period. reproductive status: 20. female participants of childbearing potential must agree to use effective contraception for sexual activity that may lead to pregnancy while on study until at least 30 days after the last dose of the study vaccine. effective contraception for female participants includes: - intrauterine device (iud), or - hormonal contraception (oral/ injectable/ implant/ transdermal etc.) or; 21. non-sterile male participants must agree to use a condom while on study until at least 30 days after the last dose of the study vaccine. or; 22. participant must not be of reproductive potential or sterile(as verified by medical records), such as: - having been diagnosed with menopause(with no menses for 1 year) - having undergone hysterectomy, bilateral oophorectomy or orchidectomy - having undergone surgical sterilization (e.g., vasectomy, tubal ligation)

inclusion criteria 1. adults, age 18 - 50 years, inclusive, at time of first study vaccination. 2. able to understand and provide a signed informed consent that fulfils the relevant institutional review board (irb) or independent ethics committee (iec) guidelines. 3. agrees to the collection of biospecimens (e.g. nasopharyngeal [np] swabs) and venous blood per protocol. 4. ability to attend required study visits and return for adequate follow-up, as required by this protocol. 5. body mass index (bmi) < 30.00 kg/m2 6. temperature < 38.0°c on day of first study vaccination. 7. good general health as shown by medical history, physical exam, and screening laboratory tests 8. screen negative for tuberculosis per local screening guidelines 9. male participants should all be at low risk of hiv acquisition based on pre-specified, validated criteria(laher 2014) i.e. answering yes to any of the following questions: 1. are you sexually abstinent? 2. are you in a mutually monogamous relationship with a known hiv-uninfected partner? 3. have you had only one partner in the preceding 12 months who is believed to be hiv-uninfected and with whom condoms were used regularly? laboratory inclusion values/ results: 10. alanine aminotransferase (alt) <1.1 times the upper limit of normal 11. serum creatinine <80 umol/l in females and <106 umol/l in males 12. haemoglobin >12.0g/dl in females and >13.5g/dl in males 13. platelets >150 x 109/l in all participants 14. no serological evidence of chronic infection with hepatitis b (hepatitis b surface antigen (hepbsag) negative by a locally approved assay) done during the screening period 15. no serological evidence of chronic infection with hepatitis c (hepatitis c antibody(anti-hcv) negative by a locally approved assay) done during the screening period 16. negative for sars-cov-2 (qpcr test) on np swab(or other appropriate respiratory specimen) within 3 days prior to the first study vaccination 17. no serological evidence of prior infection with sars-cov-2 (by a locally approved assay) done during the screening period 18. a negative serum or urine pregnancy test during screening and on the day of and prior to each dose must be documented before the vaccine is administered to a female participant. 19. negative for hiv-1 and -2 on blood test(by either 2 rapid tests or an elisa, both must be locally approved assays) done during the screening period. reproductive status: 20. female participants of childbearing potential must agree to use effective contraception for sexual activity that may lead to pregnancy while on study until at least 30 days after the last dose of the study vaccine. effective contraception for female participants includes: - intrauterine device (iud), or - hormonal contraception (oral/ injectable/ implant/ transdermal etc.) or; 21. non-sterile male participants must agree to use a condom while on study until at least 30 days after the last dose of the study vaccine. or; 22. participant must not be of reproductive potential or sterile(as verified by medical records), such as: - having been diagnosed with menopause(with no menses for 1 year) - having undergone hysterectomy, bilateral oophorectomy or orchidectomy - having undergone surgical sterilization (e.g., vasectomy, tubal ligation)